Sagetis Biotech is devoted to developing an innovative polymeric technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. 
Privately funded and based in Barcelona, Sagetis Biotech is developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.

The VIROSHIELD™ coating technology is able to modify the behavior of oncolytic viruses, improving their therapeutic effect by different means. The coated oncolytic adenoviruses are protected against pre-existing neutralizing antibodies, by masking their surface antigenic epitopes, while preserving their transduction capability.

Viroshield technology
Viroshield technology
Featured Posts

SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR RETROVIRAL AND PLASMID-BASED APPLICATIONS

March 29, 2019

1/4
Please reload

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy